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Colistin-resistant carbapenemase-producing
isolates among Klebsiella spp. and Acinetobacter
baumannii in Tripoli, Libya
Sir,
The emergence of acquired carbapenemases is a serious threat
to public health worldwide, forcing the use of last-resort
antibiotics such as polymyxins. Use of such molecules had recently
led to the emergence of colistin-resistant carbapenemase-produc-
ing isolates, leaving only a few therapeutic options for the near
future. Here we report the identiﬁcation of colistin-resistant
isolates among a collection carbapenemase-producing Enter-
obacteriaceae and Acinetobacter baumannii isolates.
A total of 61 imipenem-non-susceptible isolates were recovered
from different clinical samples from patients in Tripoli Medical
Centre (Tripoli, Libya) between 2014 and 2015. Among this
collection, 32/61 were identiﬁed as Klebsiella pneumoniae, 28/61
as A. baumannii and 1/61 as Klebsiella oxytoca using API1 gallery
(bioMérieux, Marcy-l’Étoile, France).
Antimicrobial susceptibility testing was performed according to
Clinical and Laboratory Standards Institute (CLSI) recommenda-
tions. Carbapenemase activity was determined using the RAP-
IDEC1 CARBA NP test (bioMérieux) for Enterobacteriaceae and the
modiﬁed CarbAcineto NP test for A. baumannii, showing positive
results for all isolates. Resistance to colistin was determined with
the Rapid PolymyxinTM NP test for Enterobacteriaceae [1].
Imipenem and colistin minimum inhibitory concentrations
(MIC) were evaluated by Etest and broth microdilution, respec-
tively. All isolates presenting a colistin MIC >2 mg/mL were
considered resistant. All data are summarised in Table 1.
The resistance phenotype towards other families of anti-
biotics was determined using the standard disk diffusion
method. All of the isolates presented a multidrug-resistant
phenotype. Molecular investigations involved the detection of
carbapenemases, 16S rRNA methylases and colistin resistance-
related genes by PCR ampliﬁcation using speciﬁc primers,
followed by sequencing (Microsynth AG, Balgach, Switzerland).
the 28 A. baumannii isolates were positive for the blaOXA-23 gene
and 12/28 were positive for the armA 16S rRNA methylase-
encoding gene conferring high-level resistance to aminoglyco-
sides. In addition, 5/28 isolates were resistant to colistin with an
MIC between 4 mg/mL and 128 mg/mL with an unknown resistance
mechanism.
Among the 33 carbapenem-resistant Klebsiella spp. isolates, 28/
33 and 20/33 were positive by PCR for the blaOXA-48 and blaNDM-1
genes, respectively. Noteworthy, 15/33 isolates were positive for
both carbapenemase genes. Six isolates were found to be resistant
to colistin with an MIC ranging between 64 mg/mL and 128 mg/mL
(Table 1). Noteworthy, the 16S rRNA methylase-encoding gene
rmtC was detected in three K. pneumoniae isolates and one K.
oxytoca isolate.
The clonal relationship of the Klebsiella and Acinetobacter
isolates was evaluated by pulsed-ﬁeld gel electrophoresis (PFGE).
Brieﬂy, total DNA from bacterial isolates was digested by XbaI or
ApaI restriction enzymes (New England Biolabs, Ipswich, MA) for
the Klebsiella and Acinetobacter isolates, respectively. The generat-
ed fragments were separated using a CHEF-DR1 III System (Bio-
Rad) and the different pulsotypes were identiﬁed using the
MultiVariate Statistics Package (MVSP) software. All PFGE proﬁles
showing a similarity coefﬁcient >0.8 were assigned to the same
cluster. Multilocus sequence typing (MLST) was performed for the
colistin-resistant isolates and sequence types (STs) were assigned
using the online databases http://bigsdb.web.pasteur.fr/klebsiella/
klebsiella.html and https://pubmlst.org/bigsdb?db=pubmlst_a-
baumannii_pasteur_seqdef. A total of 11 different pulsotypes
were identiﬁed among the K. pneumoniae collection, whilst 12
pulsotypes were detected among the Acinetobacter collection
(Table 1). The six colistin-resistant K. pneumoniae isolates carried
both the blaOXA-48 and blaNDM-1 carbapenemase genes. MLST
analysis revealed that these isolates belonged to ST101. Insertion of
an insertion sequence (IS) identiﬁed as IS903B into the mgrB gene
between nucleotides 107 and 108 for Kp65 and Kp82 isolates and
insertion of an IS1R mobile element in the promotor region of the
mgrB gene for Kp173, Kp174, Kp190 and Kp191 isolates (44
nucleotides before the GTG start codon) were detected by PCR
ampliﬁcation. These IS elements are likely to modify MgrB
expression and to be responsible for the high-level colistin
resistance observed in these isolates, as has been described
previously [2]. PCR experiments did not reveal the presence of the
mcr-like plasmid-mediated colistin resistance genes.
Monitoring the occurrence of multidrug-resistant bacteria is
crucial to avoid the spread of such isolates in clinical facilities.
Little information is known about the dissemination of
carbapenemase-producers in Libya and only a few clinical cases
of OXA-48-producing isolates recovered from Libyan refugees in
Europe have been described [3,4]. However, more recently, an
epidemiological study described a collection of NDM-1 and OXA-
23 carbapenemase-producing A. baumannii in a Libyan hospital [5].
Here we described multiresistant K. pneumoniae and A. baumannii
isolates. To the best of our knowledge, this is the ﬁrst study
describing colistin-resistant and 16S RNA methylase-producing
isolates in that area. This study underlines that multidrug
resistance, possibly leading to pandrug resistance, may be
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Table 1
Genotypic and phenotypic features of the collection of imipenem-non-susceptible Acinetobacter baumannii and Klebsiella spp. isolates.
Strain ID Species Pulsotype (MLST) Sample MIC (mg/mL) Resistance gene(s) Resistance phenotype
IPM COL
A37 Ab 10 (ST2) Sputum >32 128 armA, blaOXA-23 AMK/CHL/COL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A29 Ab 1 (ST164) CSF >32 32 blaOXA-23 CHL/COL/CIP/GEN/IPM/TET/TOB
A11 Ab 3 (ST745) Eye >32 8 blaOXA-23 CHL/COL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A13 Ab 4 (ND) Pleural ﬂuid >32 4 blaOXA-23 CHL/COL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A28 Ab 11 (ST164) Sputum >32 4 blaOXA-23 CHL/COL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A31 Ab 3 (ST745) ETT >32 1 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A33 Ab 6 (ST2) Blood >32 2 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A34 Ab 8 (ST2) Urine >32 0.5 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A36 Ab 9 (ST2) Central line >32 1 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A76 Ab 8 (ST2) Urine >32 2 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A87 Ab 6 (ST2) Ear >32 0.5 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A19-a Ab 5 (ST2) Urine >32 0.25 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A91 Ab 9 (ST2) Swab >32 0.5 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A92 Ab 9 (ST2) Sputum >32 0.25 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A23 Ab 5 (ST2) Blood >32 1 blaOXA-23 CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A20-a Ab 5 (ST2) Wound >32 1 armA, blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A32 Ab 7 (new ST) Blood >32 1 blaOXA-23 CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A7 Ab 1 (ST164) Blood >32 0.5 blaOXA-23 AMK/CHL/CIP/GEN/IPM/TET/TOB
A15 Ab 3 (ST745) Eye >32 0.5 blaOXA-23 AMK/CHL/CIP/IPM/SUL/SXT/TET/TOB
A24 Ab 6 (ST2) Blood >32 0.5 blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A27 Ab 2 (ST164) ETT >32 0.5 blaOXA-23 AMK/CHL/CIP/GEN/IPM/TET/TOB
A86 Ab 6 (ST2) Central line >32 0.5 blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A8 Ab 1 (ST164) ETT >32 0.25 blaOXA-23 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
A17 Ab 2 (ST164) UVC >32 0.25 blaOXA-23 CHL/CIP/GEN/IPM/SUL/TET/TOB
A35 Ab 1 (ST164) CSF >32 0.25 armA, blaOXA-23 AMK/CIP/GEN/IPM/SUL/SXT/TET/TOB
A39 Ab 12 (ST164) Swab >32 0.25 blaOXA-23 AMK/CHL/CIP/GEN/IPM/TET/TOB
A10 Ab 2 (ST164) UVC >32 0.125 blaOXA-23 AMK/CHL/CIP/GEN/IPM/TET/TOB
A16 Ab 2 (ST164) UVC >32 0.125 blaOXA-23 AMK/CIP/GEN/IPM/SUL/TET/TOB
Kp173 Kp 1 (ST101) Pus 16 128 blaOXA-48, blaNDM-1 CIP/COL/GEN/IPM/SUL/SXT/TET/TOB
Kp174 Kp 1 (ST101) Blood 16 64 blaOXA-48, blaNDM-1 CIP/COL/GEN/IPM/SUL/SXT/TET/TOB
Kp190 Kp 1 (ST101) Blood 16 128 blaOXA-48, blaNDM-1 CIP/COL/GEN/IPM/SUL/TET/TOB
Kp191 Kp 1 (ST101) Sputum 16 128 blaOXA-48, blaNDM-1 CIP/COL/GEN/IPM/SUL/TET/TOB
Kp65 Kp 2 (ST101) Urine 2 64 blaOXA-48, blaNDM-1 AMK/CIP/COL/GEN/IPM/SXT/TET/TOB
Kp82 Kp 2 (ST101) Swab 3 64 blaOXA-48, blaNDM-1 AMK/CIP/COL/GEN/IPM/SXT/TET/TOB
Kp50 Kp 11 (ST15) Sputum 3 0.125 blaOXA-48, blaNDM-1, rmtC AMK/CIP/GEN/IPM/SUL/SXT/TOB
Kp69 Ko 9 (ND) Central line 8 0.125 blaOXA-48, blaNDM-1, rmtC AMK/GEN/IPM/SUL/TOB
Kp93 Kp 3 (ST101) ETT 3 0.125 blaOXA-48, blaNDM-1, rmtC AMK/CIP/GEN/IPM/SUL/SXT/TET/TOB
Kp42 Kp 8 (ST147) Wound 1 0.125 blaOXA-48, blaNDM-1 CHL/CIP/GEN/IPM/TET/TOB
Kp51 Kp 11 (ST15) Urine >32 0.125 blaOXA-48, blaNDM-1, rmtC AMK/CIP/GEN/IPM/SUL/SXT/TOB
Kp53 Kp 7 (ST147) Swab 1 0.125 blaOXA-48, blaNDM-1 CIP/GEN/IPM/SUL/SXT/TET/TOB
Kp58 Kp 7 (ST147) Urine 1 0.125 blaOXA-48, blaNDM-1 CIP/GEN/IPM//TET/TOB
Kp61 Kp 10 (ST11) ETT >32 0.125 blaOXA-48, blaNDM-1 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TET/TOB
Kp52 Kp 7 (ST147) Blood 1 0.125 blaOXA-48, blaNDM-1 CIP/GEN/SUL/SXT/TET/TOB
Kp59 Kp 10 (ST11) Catheter >32 0.125 blaNDM-1 AMK/CHL/CIP/GEN/IPM/SUL/SXT/TOB
Kp60 Kp 10 (ST11) Swab >32 0.125 blaNDM-1 AMK/CIP/GEN/IPM/SUL/SXT/TOB
Kp78 Kp 2 (ST101) Urine >32 0.125 blaNDM-1 CIP/GEN/IPM/SUL/TET/TOB
Kp94 Kp 7 (ST147) Nose 0.5 0.125 blaNDM-1 CIP/GEN/SUL/SXT/TET/TOB
Kp12 Kp 5 (ST405) Wound 1 0.125 blaNDM-1 CIP/GEN/IPM/SUL/SXT/TET/TOB
Kp25 Kp 2 (ST101) Wound 3 0.125 blaOXA-48 CIP/GEN/IPM/SXT/TET/TOB
Kp88 Kp 5 (ST405) Blood 0.75 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Kp89 Kp 5 (ST405) ETT 0.75 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Kp84 Kp 2 (ST101) ETT 0.38 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Kp95 Kp 3 (ST101) ETT 0.38 0.125 blaOXA-48 CIP/GEN/TET/TOB
Kp49 Kp 8 (ST147) Sputum 0.5 0.125 blaOXA-48 AMK/CIP/GEN/SUL/SXT/TET/TOB
Kp56 Kp 6 (ST405) ETT 0.5 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Kp57 Kp 6 (ST405) Blood 0.5 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Kp70 Kp 6 (ST405) Blood 0.5 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Kp72 Kp 5 (ST405) ETT 0.5 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Kp80 Kp 4 (ST45) ETT 0.5 0.125 blaOXA-48 GEN/SXT/TET/TOB
Kp71 Kp 2 (ST101) Blood 0.5 0.125 blaOXA-48 CIP/GEN/TET/TOB
Kp85 Kp 3 (ST101) ETT 0.5 0.125 blaOXA-48 CIP/GEN/SUL/SXT/TET/TOB
Ab, Acinetobacter baumannii; Kp, Klebsiella pneumoniae; Ko, Klebsiella oxytoca; MLST, multilocus sequence typing; ND, not determined; CSF, cerebrospinal ﬂuid; ETT,
endotracheal tube; UVC, umbilical vein catheter; MIC, minimum inhibitory concentration; IPM, imipenem; COL, colistin; AMK, amikacin; CHL, chloramphenicol; CIP,
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